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Drug resistance in fecal bacteria was high in
Wayampis Amerindians who did not take antibacterial
agents and were not hospitalized for 1 year. In the
Wayampis Amerindians, an isolated traditional community
in French Guyana, antibacterial use was 0.64 treatments
per person per year. Hospitalization rate was 6.1% per
year. Antibacterial drug–resistant bacteria can spread in
persons who are not taking antibacterial agents.
A
ntibacterial-resistant bacteria can spread in persons not
taking antibacterial agents. This resistance results
from contaminated food, antibacterial drug exposure, and
cross-contamination from humans or animals. Antibacterial
resistance is high in developing countries (1) because of
self-medication, the suboptimal quality of antibacterial
drugs, and poor community and patient hygiene (2).
To analyze the role of cross-transmission on the resist-
ance of fecal commensal enterobacteria, we conducted a
study from October 1 through 15, 2001, among Wayampis
Amerindians who lived in the most southern part of French
Guyana, in an isolated, ethnically homogeneous, tradition-
al community. The community was made up of 184 males
and 204 females (193 children <15 years and 195 adults),
who were evenly distributed in three villages (Z, n = 248;
TS, n = 85; and YP, n = 55). Access to the villages was
restricted to residents, and the sites were isolated, 100 km
south of the closest village. Villagers shared large huts
(13.9  + 8.6 inhabitants per hut [range 4–38]) with no
latrines or hygienic facilities, and used a single spot on the
river for drinking, bathing, and disposal of human waste.
They ate only local food (crops grown in a traditional man-
ner and meat from fishing or hunting). They did not raise
farm animals except a few free-running chickens. A para-
medic officer permanently residing in Z provided the only
antibacterial agents in the vicinity and recorded their dis-
pensation. When necessary, the villagers were hospitalized
in Cayenne, the capital of French Guyana. Medical care
was free.
The Study
Rates of antibacterial exposure were calculated as the
ratio of the number of treatments prescribed divided by the
number of villagers and compared by using analysis of
variance. Chi-square-tests or Fisher exact tests were used
for binary variables. During the year preceding the study,
24 (6.1%) of 388 villagers had been hospitalized; 235
(60.6%) had received no treatment with antibacterial
agents. One hundred fifty-three (39.4%) of the villagers
had received 250 courses of antibacterial treatment. Of the
therapeutic agents used, 72 (28.8%) were amino-
penicillins, 111 (44.4%) were metronidazole, 36 (14.4%)
were macrolides, and 31 (12.4%) were  different anti-
bacterial agents (17 penicillin M, 2 penicillin G, 7
cotrimoxazole, 3 cyclines, and 2 first-generation
cephalosporins). Ninety-eight (25.3%) villagers had
received one course of treatment, 30 (7.7%) received 2
courses of treatment, 13 (3.4%) received 3 courses of
treatment, and 12 (2.1%) received >4 courses of treatment.
Overall antibacterial and aminopenicillin exposures were
significantly higher in village Z, where the paramedical
officer resided (Table 1), and in children.
In October 1999, one of the investigators (V.J. or A.A.)
asked each adult to participate in the study. Children were
recruited with the help of the teachers at school. Exclusion
criteria were fever, diarrhea, or acute infection, and a stay
outside the study zone, a history of hospitalization (veri-
fied by Cayenne’s hospital records), or treatment with an
antibacterial agent (verified by records of the paramedical
officer) during the preceding year. We chose this period for
surveillance because it was the longest period for which
information was available. Information was verified by
one of the investigators.
The study was approved by the Comité Consultatif de
Protection des Personnes se prêtant à des Recherches
Biomédicales (CCPPRB) of Cayenne and by the adminis-
trative authorities of French Guyana and was authorized by
the French Ministry of Health. Before participants were
included, the study was presented to the villagers, with the
aid of the chief of the village who explained that some of
them would be asked to participate. Consent was obtained
before participants were included in the study.
Study participants were asked to bring fresh stool sam-
ples (unformed samples were excluded) to the paramedic
officers. The samples were then mixed into brain-heart
infusion broth with 10% glycerol and frozen in liquid
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Hospitalier de Cayenne, French Guyananitrogen. Upon harvesting, 25 µL of broth was added to 2
mL of brain-heart infusion broth, incubated for 4 h, and
plated on cetrimide, Chapman, and bile-esculin-acid agar
containing 10 mg/L of vancomycin (after an enrichment
step of 18 h in broth containing 1 mg/L of vancomycin) to
detect Pseudomonas aeruginosa, Staphylococcus aureus,
and vancomycin-resistant enterococci, respectively.
Antibacterial-resistant gram-negative bacteria were detect-
ed by using two separate methods. The first method
explored the predominant flora. Drigalski agar plates were
plated with the fecal dilutions; after 48 h growth, five
colonies were randomly selected, identified, and tested for
antibacterial susceptibility as described (http://www.sfm.
asso.fr). A participant was defined as colonized in the pre-
dominant flora with gram-negative bacteria resistant to a
given antibacterial agent when at least one strain resistant
to this antibacterial agent was isolated. The second method
explored the subdominant flora. Drigalski agar plates were
supplemented with either ampicillin (10 mg/L), cef-
tazidime (2 mg/L), streptomycin (20 mg/L), kanamycin
(20 mg/L), chloramphenicol (20 mg/L), tetracycline
(10 mg/L), or nalidixic acid (50 mg/L) (3), used within 24
h after preparation, and kept at 4°C until used. The plates
were plated with the fecal dilutions, incubated for 48 h,
and inspected for lactose-positive and lactose-negative
colonies. Aparticipant was defined as colonized in the sub-
dominant flora with gram-negative bacteria resistant to a
given antibacterial agent when at least one colony grew on
agar containing the corresponding antibacterial agent. No
further identification was performed; for quality control
purposes, some positive plates were randomly selected for
confirmation of antibacterial susceptibility of the isolates.
Because the number were few and unexpected, colonies
that grew on agar containing ceftazidime were all identi-
fied by conventional methods or 16S RNA gene sequenc-
ing (4), when needed; their antibacterial susceptibility was
tested; and genes encoding for extended spectrum β-lacta-
mase were characterized, when needed, by polymerase
chain reaction and sequencing (5). When needed, the clon-
ality of isolates was determined by using pulsed-field gel
electrophoresis (PFGE) (6).
The fecal flora was thus analyzed in a subgroup of 93
volunteers (39 men and 54 women; 41.2% from village
TS, 18.1% from village Z, and 23.6% village YP
[p < 0.001]) who met the inclusion criteria cited above,
representing 93 (23.9%) of 388 villagers and 93 (39.6%) of
235 who had not received antibacterial agents for 1 year.
Carriage of resistant gram-negative bacteria in
subdominant flora of these 93 volunteers ranged from
>90% for those resistant to ampicillin, streptomycin, and
tetracycline to 7% for those resistant to nalidixic acid
(Table 2), with no significant difference for sex or age. We
found no association between the rate of resistance in the
study participants and the number persons who used
antibacterial agents or of children in the hut. Fourteen
participants (all living in village Z but not in the same hut)
were colonized by gram-negative bacteria resistant to
ceftazidime, including three Escherichia coli strains with a
similar pattern by PFGE that produced BlaTEM-52 extended
spectrum β-lactamase. Nine participants (three, one, and
five living in villages TS, YP and Z, respectively, and only
two in the same hut) were colonized by strains of
Acinetobacter baumannii sharing the same susceptibility
pattern. Two participants (one in village TS and one in
village Z) were colonized by strains of Ochrobactrum spp.
Neither  S. aureus  or  P. aeruginosa  were isolated. One
participant from village Z was colonized by a vancomycin-
resistant strain of Enterococcus gallinarum.
Resistance rates in the predominant flora were from
95% to tetracycline to 0% to ceftazidime and nalidixic
acid, with no significant differences between adults and
children, men and women, or villages. Although they were
not chosen randomly, approximately 40% of the untreated
villagers were included, which suggests that the group was
representative of the whole community.
Recently, high resistance rates were also reported in
remote populations from Bolivia (7) and Nepal (2). Here,
however, we have provided additional information on
exposure to antibacterial drugs and hospitalizations of the
study participants. In the villages studied, the global anti-
bacterial exposure (0.64 treatments/person/year) was
roughly half that of France (8), thus close to the mean rate
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Table 1. Antibacterial exposure in 388 Wayampi Amerindians from three villages in southern French Guyana during the year preceding 
the study
a 
Frequency of antibacterial exposure in (%) 
Antibacterial agents  TS (n = 85)  YP (n = 55)  Z (n = 248)  Total (N = 388)  p value
b 
Aminopenicillins  5.9  14.6  23.8  18.6  0.007 
Metronidazole  16.5  30.9  32.3  28.6  0.15 
Macrolides  8.2  1.8  11.3  9.3  0.2 
Other  5.8  7.3  8.9  8.0  0.7 
Overall  36.5  54.6  76.2  64.4  0.007 
aFrequency of antibacterial exposure was calculated by dividing the number of all antibacterial courses during the year preceding the study by the number 
of persons in each village. 
bAnalysis of variance (ANOVA). of European Union countries (9), which stresses the indi-
rect impact of antibacterial use on persons who do not use
them. Unrecorded antibacterial drug use in the participants
was unlikely because no alternate sources of antibacterial
agents existed, and free antibacterial agents were provided
when needed, decreasing the likelihood of nonprescribed
use or sharing of antibacterial agents by family members.
Our results can be compared only to those of studies
performed with similar methods and in persons who also
had not taken antibacterial drugs. For instance, resistance
rates of predominant E. coli in the Wayampis population to
ampicillin, tetracycline, and streptomycin were higher than
that observed in French bank workers (10) or Bostonian
children (1), but close to that reported in children from
Venezuela and China (1). That the resistance rate was high-
er in the Wayampis Amerindians than in the French work-
ers was unexpected, considering the higher levels of
antibacterial drug use in the French community. These data
suggested frequent cross-transmission likely attributable to
poor hygiene (1,2). Cross-transmission is common among
households, even in industrialized countries (11). Its role in
the spread of drug-resistant bacteria among the Wayampis
Amerindians, even in adults, was further indicated by the
lack of difference in resistance rates according to age.
Resistance to quinolones, which were not used in this
community, was lower than in Europe (12), which illus-
trates the specificity of selective pressure. Third-genera-
tion cephalosporins were also not used. Thus, how samples
from three participants were colonized by an E. coli–carry-
ing BlaTEM-52 (13), an extended-spectrum β-lactamase-gene
found only in hospitals, is difficult to explain. However,
enterobacteria that produced an extended spectrum β-lac-
tamase were prevalent at the time in the Cayenne hospital
(B.M., unpub. data). Since the three persons with the
BlaTEM-52 -colonized samples had not been hospitalized
during the previous year, possibly this strain, or a different
one, carrying BlaTEM-52 was acquired and spread in the
community by one of the 24 villagers hospitalized during
the year preceding the study. Extended-spectrum β-lacta-
mase can disseminate in the community (14). We cannot
exclude that the three BlaTEM-52 carriers had been hospital-
ized earlier. If they were hospitalized and colonized during
hospitalization, this colonization would not have been like-
ly to have persisted for so long; indeed, carriage of resist-
ant nasal staphylococci can last for months, but resistance
in intestinal enterobacteria decreases within 10–20 days
after selective pressure ends (15).
Conclusions
Antibacterial agents in the food chain are a source of
resistance in industrialized countries (16). In our study,
food was strictly local but may have been the source of the
wild-type naturally resistant A. baumannii and
Ochrobactrum spp. strains that we isolated. Environmental
species have also been isolated in Amerindians living in
nearby (formerly Dutch) Guyana (17).
Because data confirmed the lack of direct antibacterial
drug exposure in our study participants, the results demon-
strate that, once resistance elements are introduced into a
population, moderate use of antibacterial drugs in the envi-
ronment is enough to maintain them in intestinal bacteria
when sanitary conditions are poor.
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Table 2. Prevalence of carriage of gram-negative bacteria resistant to various antibacterial agents in the predominant and the 
subdominant fecal flora of the 93 study participants
a 
Predominant flora











negative (%)  Any (%) 
Ampicillin  51 (55)  19 (21)  5 (5)  2 (2)  77 (83)  89 (96)  31 (33)  93 (100) 
Ceftazidime  0  0  0  0  0  3
c (4)  11
d (12)  14 (15) 
Nalidixic acid  0  0  0  0  0  7
e (8)  0  7 (8) 
Pefloxacine  0  0  0  0  0  ND  ND  ND 
Streptomycin  42 (45)  2 (2)  0  0  44 (47)  83 (90)  19 (21)  86 (93) 
Kanamycin  5 (5)  0  0  0  5 (5)  45 (49)  4 (5)  47 (51) 
Tetracycline  59 (63)  14 (15)  0  2 (2)  75 (81)  86 (93)  25 (27)  86 (93) 
Cotrimoxazole  27 (29)  0  0  0  27 (29)  ND  ND  ND 
Chloramphenicol  22 (24)  0  0  0  22 (24)  48 (52)  27 (29)  60 (67) 
aAccounting for 23.9% (93 of 388) of the global population of the villages studied and not significantly different from it for male/female ratio or age 
distribution. 
bBacteria with intermediate susceptibility were categorized as resistant.  
cExtended spectrum β-lactamase E. coli. 
dAcinetobacter baumanni: 9 (all with the same susceptibility pattern including susceptibility to ureidopenicillins, third -generation cephalosporins, 
aminoglycosides, and quinolones) and Ochrobactrum spp. (identified by 16s RNA genes sequencing): 2.  
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